



A Phase 3 Clinical Study of **Vepugratinib**
Combined With Enfortumab Vedotin and
Pembrolizumab for the Treatment of Locally
Advanced/Metastatic Urothelial Cancer With
a Change in the **FGFR3** Gene

● Looking for participants

What is the purpose of this study?

To learn if a combination of vepugratinib with standard of care bladder cancer medicines is more effective than standard of care alone in untreated advanced bladder cancer patients with a change in their *FGFR3* gene.

What is FGFR3?

- **FGFR3** stands for **Fibroblast Growth Factor Receptor 3**
- *FGFR3* is a gene that everyone has but undergoes a change in some people, resulting in cancer in the bladder, urinary tract, or other areas of the body
- To look for a change(s) in the *FGFR3* gene, a doctor will perform a test using the patient's blood and/or tumor tissue

Who can participate in the study?


This study is for patients:

- Who are 18 years or older
- Who have **untreated locally advanced or metastatic urothelial carcinoma** (a type of bladder cancer that has grown nearby or spread to other parts of the body), with a change in the **FGFR3** gene

Please look at the study website for a complete list of what is needed to participate.

What is the plan for the study?

- This is a randomized, double-blinded study, meaning the doctors and the patients will not know whether they are receiving vepugratinib or a placebo (a treatment that looks like a real treatment, but does not have any therapeutic effect)
- Patients will receive either **vepugratinib or a placebo, in combination with standard of care** bladder cancer medicines^a



^aIf approved by a physician, patients may receive one cycle of standard of care bladder cancer medicines prior to going on study. Vepugratinib and placebo are taken orally, and enfortumab vedotin + pembrolizumab are given through a vein (intravenous infusion). R=randomization.

What is the main goal of the study?

The main goal of the study is to learn about the **effectiveness, safety, and side effects** of vepugratinib in combination with standard of care bladder cancer medicines.

Please look at the study website for a complete list of the study goals.

For more information, please visit the study website:



<https://clinicaltrials.gov/study/NCT07218380>

Lilly Trials Support:
LillyTrials@lilly.com
The use of the investigational medicine is experimental.
Not all risks are known. There is no guarantee that a participant's cancer will improve when taking part in this study.

There may be multiple sites in this clinical trial. If you have further questions or interest in this clinical trial, please contact -
Telephone: 1-877-285-4559 or 1-317-615-4559
Email: LillyTrials@lilly.com

